Evaluation of Socio-demographic Factors and Comorbidities in Adult Hemophilia Patients

Yıl 2024, Cilt: 8 Sayı: 2, 483 - 489, 31.05.2024

Fatma Keklik Karadağ Zühal Demirci Fatoş Dilan Köseoğlu Güray Saydam Fahri Şahin

https://doi.org/10.30621/jbachs.1416117

Öz

Evaluation of Socio-demographic Factors and Comorbidities in Adult Hemophilia Patients

Öz

Purpose: The association between socio-demographic factors and hemophilia status and the prevalence of comorbidities were evaluated.
Material and Methods: Patients with hemophilia A (n=111) and B (n=24) who were filled a questionnaire form about their sociodemographic factors were included in our study. Factor and inhibitor levels, comorbidities, factor replacement therapies, hemophilic arthropathy, viral status and annual bleeding episodes were recorded.
Results: Median age was 39 years in 135 hemophilia patients and 63.1 % of all the patients had severe hemophilia which was significantly higher among hemophilia A patients (p=0.002). Most of the patients (74.8%) were treated with prophylactic factor replacement therapy. Inhibitor status was positive in 8.9% of all patients. Unemployment rate was found 33.3%. Annual bleeding episodes were higher in patients who had a job. Most of the patients (60 %) were graduated from at least high school. The prevalence of cardiovascular disease, hypertension, diabetes mellitus and obesity were 6.7%; 17.8%, 13.3%, 11.9% respectively. Although there is no association between the obesity and annual bleeding episodes, right ankle was the most affected joint in overweight/obese patients.
Conclusion: Age-related comorbidities and the relation of hemophilia status and social life are needed to be more investigated.

Anahtar Kelimeler

Hemophilia, comorbidity, sociodemographic, adult

Etik Beyan

The study was approved by Ege University, Clinical Research Ethics Committee (Date: 09.08.2016, Decision No: 16-7/1).

Destekleyen Kurum

The authors declare no conflict of interest.

Teşekkür

None

Kaynakça

• Nathwani AC. Gene therapy for hemophilia. Hematology Am Soc Hematol Educ Program. 2019;2019(1):1-8.
• Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with haemophilia. Br J Haematol. 2010;148(4):522-33.
• Aledort L, Bullinger M, von Mackensen S, et al. Why should we care about quality of life in persons with haemophilia? Haemophilia. 2012;18(3):e154-7.
• Kempton CL, Makris M, Holme PA. Management of comorbidities in haemophilia. Haemophilia. 2021;27 Suppl 3:37-45.
• Mannucci PM. Aging with Hemophilia: The Challenge of Appropriate Drug Prescription. Mediterr J Hematol Infect Dis. 2019;11(1):e2019056.
• Alam AU, Goodyear MD, Wu C, et al. Increased acute care utilisation, comorbidities and mortality in adults with haemophilia: A population-based cohort study from 2012 to 2019. Haemophilia. 2023;29(1):219-229.
• Shapiro S, Makris M. Haemophilia and ageing. Br J Haematol. 2019;184(5):712-720.
• Skjefstad K, Solberg O, Glosli H, et al. Life expectancy and cause of death in individuals with haemophilia A and B in Norway, 1986-2018. Eur J Haematol. 2020;105(5):608-615.
• Kavakli K, Aktuglu G, Kemahli S, et al. Inhibitor screening for patients with hemophilia in Turkey. Turk J Haematol. 2006;23(1):25-32.
• Ghosh K, Shetty S, Kulkarni B, et al. Development of inhibitors in patients with haemophilia from India. Haemophilia. 2001;7(3):273-8.
• Oren H, Yaprak I, Irken G. Factor VIII inhibitors in patients with hemophilia A. Acta Haematol. 1999;102(1):42-6.
• Lusher JM, Arkin S, Abildgaard CF, et al. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med. 1993;328(7):453-9.
• Marchesini E, Oliovecchio E, Coppola A, et al. Comorbidities in persons with haemophilia aged 60 years or more compared with age-matched people from the general population. Haemophilia. 2018;24(1):e6-e10.
• Curtis R, Baker J, Riske B, et al. Young adults with hemophilia in the U.S.: demographics, comorbidities, and health status. Am J Hematol. 2015;90 Suppl 2:S11-6.
• Sun J, Zhao Y, Yang R, et al. The demographics, treatment characteristics and quality of life of adult people with haemophilia in China - results from the HERO study. Haemophilia. 2017;23(1):89-97.
• Fransen van de Putte DE, Fischer K, Makris M, et al. Increased prevalence of hypertension in haemophilia patients. Thromb Haemost. 2012;108(4):750-5.
• Siboni SM, Mannucci PM, Gringeri A, et al. Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. J Thromb Haemost. 2009;7(5):780-6.
• Chang CY, Li TY, Cheng SN, et al. Obesity and overweight in patients with hemophilia: Prevalence by age, clinical correlates, and impact on joint bleeding. J Chin Med Assoc. 2019 ;82(4):289-294.
• Santos EM, Silva JM, Barbosa AN, et al. Clinico-epidemiological and sociodemographic profile of patients with hemophilia in the Brazilian Amazon: High prevalence of hepatitis C infection and its possible corrrelation with inhibitor development. Front Public Health. 2022;10:963790.